Literature DB >> 7687622

Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

E van de Wiel-van Kemenade1, M J Ligtenberg, A J de Boer, F Buijs, H L Vos, C J Melief, J Hilkens, C G Figdor.   

Abstract

Episialin (MUC1) is a mucin-like glycoprotein abundantly expressed on most carcinoma cells. As a result of its extended and rigid structure, it reduces intercellular adhesion. We investigated whether this antiadhesion function allows tumor cells expressing high levels of episialin to escape from immune recognition. To test this hypothesis, we transfected episialin-negative (episialin-) melanoma cells (A375) with the MUC1 cDNA-encoding episialin. The results demonstrated that episialin-positive (episialin+) melanoma cells were significantly less susceptible to lysis than episialin- melanoma cells by both alloantigen or rIL-2-stimulated cytotoxic effector cells. In addition, cold target inhibition experiments with episialin+ and episialin- cells clearly demonstrated preferential lysis of episialin- cells. Furthermore, antibody blocking studies showed that lysis of episialin+, but not of episialin-, melanoma cells was predominantly dependent on the leukocyte function-associated Ag-1/intracellular adhesion molecule adhesion route, suggesting that episialin+ target cells adhere less efficiently to effector cells than episialin- target cells. This notion was supported by the observation that conjugate formation of the effector cells with episialin+ target cells was significantly impaired. From these results we conclude that over-expression of episialin as found on many tumor cells may indeed affect efficient lysis by cytotoxic lymphocytes and thus may contribute to escape from immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687622

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Authors:  S J Pettit; S Ali; E O'Flaherty; T R Griffiths; D E Neal; J A Kirby
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 2.  Mucins and blastocyst attachment.

Authors:  Amantha Thathiah; Daniel D Carson
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

3.  Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Authors:  Isabel Correa; Tim Plunkett; Anda Vlad; Arron Mungul; Jessica Candelora-Kettel; Joy M Burchell; Joyce Taylor-Papadimitriou; Olivera J Finn
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

4.  O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.

Authors:  Pushpa Premaratne; Karin Welén; Jan-Erik Damber; Gunnar C Hansson; Malin Bäckström
Journal:  Tumour Biol       Date:  2010-09-26

5.  Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells.

Authors:  J Magarian-Blander; R P Hughey; C Kinlough; P A Poland; O J Finn
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

Review 6.  Perspectives on the significance of altered glycosylation of glycoproteins in cancer.

Authors:  Y J Kim; A Varki
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

7.  MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.

Authors:  Yuichiro Suzuki; Mihoko Sutoh; Shingo Hatakeyama; Kazuyuki Mori; Hayato Yamamoto; Takuya Koie; Hisao Saitoh; Kanemitsu Yamaya; Tomihisa Funyu; Tomonori Habuchi; Yoichi Arai; Minoru Fukuda; Chikara Ohyama; Shigeru Tsuboi
Journal:  Int J Oncol       Date:  2012-03-23       Impact factor: 5.650

8.  Antigen recognition is facilitated by invadosome-like protrusions formed by memory/effector T cells.

Authors:  Peter T Sage; Laya M Varghese; Roberta Martinelli; Tracey E Sciuto; Masataka Kamei; Ann M Dvorak; Timothy A Springer; Arlene H Sharpe; Christopher V Carman
Journal:  J Immunol       Date:  2012-03-21       Impact factor: 5.422

9.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

10.  An abundantly expressed mucin-like protein from Toxocara canis infective larvae: the precursor of the larval surface coat glycoproteins.

Authors:  D Gems; R M Maizels
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.